AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics 28 February 2018
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease 07 February 2018
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage 23 January 2018
New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity 19 January 2018
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer 18 December 2017
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China 27 November 2017
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma 15 November 2017
FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma 31 October 2017
FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review 18 October 2017
Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer 11 October 2017
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD 25 September 2017
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab 12 September 2017
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma 06 September 2017
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease 29 August 2017
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack 24 August 2017
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review 02 August 2017
AstraZeneca and Merck establish strategic oncology collaboration 27 July 2017
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig 08 June 2017
AstraZeneca enters agreement with Recordati for Seloken in Europe 22 May 2017
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer 12 May 2017

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs